Literature DB >> 32054260

Rare Cytogenetic Anomalies in Two Pediatric Patients with Acute Leukemia

Süreyya Bozkurt1, Şule Ünal2, Turan Bayhan3, Fatma Gümrük2, Mualla Çetin2.   

Abstract

Entities:  

Keywords:  Acute myeloid leukemia; Rare cytogenetic anomalies; Karyotype

Mesh:

Year:  2020        PMID: 32054260      PMCID: PMC7236420          DOI: 10.4274/tjh.galenos.2020.2019.0425

Source DB:  PubMed          Journal:  Turk J Haematol        ISSN: 1300-7777            Impact factor:   1.831


× No keyword cloud information.

To the Editor,

Structural chromosomal abnormalities are frequently seen in both pediatric acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) cases [1,2,3]. Although some chromosomal abnormalities are common, other abnormalities are rarely seen [4,5]. In this study two relatively rare cytogenetic abnormalities are reported. All procedures were performed in accordance with the Helsinki Declaration and approved by the local ethics committee (Approval No: GO 16/267-45).

Case One

CALLA+ pre-B-cell ALL was diagnosed in an 8-year-old-boy. The complete blood count (CBC) at diagnosis revealed hemoglobin of 5.5 g/dL, white blood cell (WBC) count of 2.8x109/L, and platelet count of 301x109/L. He had t(1;4)(q42;q22) in all twenty metaphases as a sole abnormality (). The ALLIC-BFM-2009 treatment protocol was started. Bone marrow examination on day 15 revealed remission. The patient was diagnosed in 2006. The last follow-up visit was in December 2019 and he is still alive.

Case Two

A girl of two and half months was diagnosed with the AML FAB-M5 phenotype. She had no comorbid disease and the diepoxybutane (DEB) test for Fanconi’s anemia was negative. CBC results at diagnosis revealed hemoglobin of 10 g/dL, WBC count of 9.2x109/L,and platelet count of 365x109/L. The AML-BFM-2004 protocol was initiated. The karyotype of the patient was 46,XX,t(1;11)(p32;q23)[19]/46,XX [1]. Bone marrow aspiration of the patient showed that she had entered the remission. Herein, we report two rare translocations. t(1;4)(q42;q22) was found in Case 1 with ALL and this anomaly has been reported in one case to date according to the database in which we searched [6]. The previous case was also a pediatric ALL patient, as in our case [7]. While we found t(1;4)(q42;q22) as a sole abnormality in all metaphases, the anomaly was found in a complex karyotype in the previously reported case. The hybrid gene formed as a consequence of this t(1;4)(q42;q22) and its function are not known. Our case is the second reported case with this anomaly and thus contributes to the literature. In our second case, t(1;11)(p32;q23) was found, which has been seen in a total of seven pediatric AML cases to date [6]. The ages of patients in whom this abnormality was previously detected were between 0 and 12 years, two of them being infants; our patient was 2.5 months old. When the FAB classification of the patients was examined for the previously reported cases, M0, M1, M4, and M5 were found. Hayashi et al. [8] reported this anomaly for the first time in a 7-year-old patient with AML M1 and they did not find this anomaly at diagnosis; instead, it was detected during the remission of the patient. In our case, t(1;11)(p32;q23) was present at the time of diagnosis of acute leukemia. The result of t(1;11)(p32;q23) is the MLL-EPS15 fusion gene. The role of this fusion gene in the pathogenesis of AML is not known, but it has been suggested that the coiled-coil domains of EPS15 mediate oligomerization and activate MLL [9,10,11]. The prognostic values of rare cytogenetic anomalies are unknown. The accumulation of knowledge about rare cytogenetic anomalies detected in childhood leukemia is expected to contribute to a better understanding of the pathogenesis of these diseases.
  9 in total

1.  The localization of the HRX/ALL1 protein to specific nuclear subdomains is altered by fusion with its eps15 translocation partner.

Authors:  D Rogaia; F Grignani; R Carbone; D Riganelli; F LoCoco; T Nakamura; C M Croce; P P Di Fiore; P G Pelicci
Journal:  Cancer Res       Date:  1997-03-01       Impact factor: 12.701

Review 2.  Cytogenetics of pediatric acute myeloid leukemia.

Authors:  Kalliopi N Manola
Journal:  Eur J Haematol       Date:  2009-06-25       Impact factor: 2.997

Review 3.  Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine.

Authors:  Stephen P Hunger; Charles G Mullighan
Journal:  Blood       Date:  2015-05-21       Impact factor: 22.113

4.  Two karyotypically independent leukemic clones with the t(8;21) and 11q23 translocation in acute myeloblastic leukemia at relapse.

Authors:  Y Hayashi; S C Raimondi; F G Behm; V M Santana; D K Kalwinsky; C H Pui; J Mirro; D L Williams
Journal:  Blood       Date:  1989-05-01       Impact factor: 22.113

Review 5.  Leukemias in Children.

Authors:  Rachna Seth; Amitabh Singh
Journal:  Indian J Pediatr       Date:  2015-02-15       Impact factor: 1.967

Review 6.  Genetic Basis of Acute Lymphoblastic Leukemia.

Authors:  Ilaria Iacobucci; Charles G Mullighan
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

7.  Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features.

Authors:  F G Behm; S C Raimondi; M J Schell; A T Look; G K Rivera; C H Pui
Journal:  Blood       Date:  1992-02-15       Impact factor: 22.113

8.  New genetics and diagnosis of childhood B-cell precursor acute lymphoblastic leukemia.

Authors:  Christine Harrison
Journal:  Pediatr Rep       Date:  2011-06-22

9.  The MLL recombinome of acute leukemias in 2013.

Authors:  C Meyer; J Hofmann; T Burmeister; D Gröger; T S Park; M Emerenciano; M Pombo de Oliveira; A Renneville; P Villarese; E Macintyre; H Cavé; E Clappier; K Mass-Malo; J Zuna; J Trka; E De Braekeleer; M De Braekeleer; S H Oh; G Tsaur; L Fechina; V H J van der Velden; J J M van Dongen; E Delabesse; R Binato; M L M Silva; A Kustanovich; O Aleinikova; M H Harris; T Lund-Aho; V Juvonen; O Heidenreich; J Vormoor; W W L Choi; M Jarosova; A Kolenova; C Bueno; P Menendez; S Wehner; C Eckert; P Talmant; S Tondeur; E Lippert; E Launay; C Henry; P Ballerini; H Lapillone; M B Callanan; J M Cayuela; C Herbaux; G Cazzaniga; P M Kakadiya; S Bohlander; M Ahlmann; J R Choi; P Gameiro; D S Lee; J Krauter; P Cornillet-Lefebvre; G Te Kronnie; B W Schäfer; S Kubetzko; C N Alonso; U zur Stadt; R Sutton; N C Venn; S Izraeli; L Trakhtenbrot; H O Madsen; P Archer; J Hancock; N Cerveira; M R Teixeira; L Lo Nigro; A Möricke; M Stanulla; M Schrappe; L Sedék; T Szczepański; C M Zwaan; E A Coenen; M M van den Heuvel-Eibrink; S Strehl; M Dworzak; R Panzer-Grümayer; T Dingermann; T Klingebiel; R Marschalek
Journal:  Leukemia       Date:  2013-04-30       Impact factor: 11.528

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.